ASCO: Zoledronic acid for treament of prostate cancer
- Length: 2:24
- Rating Average: n/a
- View Count:
- Author: ecancertv
Tags: Thomas Leonard F6 768K 001
Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals. Results of Phase II study comparing Orazol (zoledronic acid in oral form) to Zometa (zoledronic acid IV) injections in treatment of prostate cancer, as presented at the ASCO Meeting, 2009. Further comment from Chief...
San Antonio Breast Cancer Symposium 2008: Zoledronic acid may have anti-tumour properties
- Length: 5:25
- Rating Average: n/a
- View Count:
- Author: ecancertv
Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9...
New Drug Being Tested to Treat Osteoporosis - VOA Story
- Length: 2:47
- Rating Average: n/a
- View Count:
- Author: MyEarbot
Tags: health osteoporosis zoledronic acid
There are a lot of myths about osteoporosis, a bone disease that leads to the thinning of bone tissue, and ultimately, to broken hips, wrists and spines. One myth is that only women get osteoporosis. Another: that only old women get it. The truth is, men can suffer from it too. So can young...
Drug Reduces Fractures and Death after Hip Fracture
- Length: 2:19
- Rating Average: 5.0' max='5' min='1' numRaters='1' rel='http://schemas.google.com/g/2005#overall from people
- View Count:
- Author: DukeMedicine
Tags: Duke study hip fracture Reclast Lyles zoledronic acid once a year
A study of 2127 patients who received the drug zoledronic acid (trade name Reclast) within 90 days of surgery for a hip fracture had a 28 percent reduction in death and were 35 percent less likely to suffer another fracture. Patients were followed for an average of 1.9 years. About 25 percent of...
Interview with Dr. Michael Gnant at 2008 ASCO Annual Meeting
- Length: 4:18
- Rating Average: n/a
- View Count:
- Author: ElsGlobalMedicalNews
Tags: EGMN medicine breast cancer michael gnant ASCO zoledronic acid Zometa Elsevier Global Medical News oncologystat
Elsevier Global Medical News/oncologystat interviews Dr. Michael Gnant on the Austrian Breast and Colorectal Cancer Study Group-12 trial. The study assessed use of zoledronic acid to prevent breast cancer recurrence in postmenopausal women. Interviewer: Mary Ellen Schneider, EGMN
STAMPEDE Trial Treatment & Patient Management.avi
- Length: 4:12
- Rating Average: n/a
- View Count:
- Author: StampedePR08
Tags: STAMPEDE Trial Treatment Patient Management Prostate Cancer Clinical Medical Reasearch Council
A number of newer treatments have recently become available and have shown initial promise against prostate cancer. Newer treatments are usually used in prostate cancer when hormone treatment is no longer effective and the cancer has started to grow again. The aim of this trial, which is called...
Possible Link between Bisphosphonates and Atrial Fibrillatio
- Length: 1:38
- Rating Average: 5.0' max='5' min='1' numRaters='1' rel='http://schemas.google.com/g/2005#overall from people
- View Count:
- Author: LawsuitGuru
Tags: Bisphosphonates Atrial Fibrillation Drug Reaction FDA Osteoporosis Reclast Fosamax
FDA has issued an early communication to healthcare professionals about a possible association between bisphosphonate drugs, which are used to treat osteoporosis, and atrial fibrillation. This issuance is part of fda's commitment to keep the public informed about ongoing safety reviews of drugs,...
Bisphosphonates and Atrial Fib in Osteoporosis Patients
- Length: 1:38
- Rating Average: n/a
- View Count:
- Author: USFoodandDrugAdmin
Tags: osteoporosis drug safety reclast fosamax actonel zometa
FDA has issued an early communication to healthcare professionals about a possible association between bisphosphonate drugs, which are used to treat osteoporosis, and atrial fibrillation. This issuance is part of fda's commitment to keep the public informed about ongoing safety reviews of drugs,...
Page: 1 of 2
